Science News

... from universities, journals, and other research organizations

A Winning Combination For The Treatment Of Cancer

ScienceDaily (Aug. 18, 2007) — The immune system does not destroy tumors even though they express molecules that should activate immune cells.

The immune system is therefore said to be tolerant of the tumors. Several molecules and cell types have been implicated in the induction of immune system tolerance to tumors, including, in mice, a small population of immune cells known as plasmacytoid dendritic cells (pDCs) that produce the enzyme indoleamine 2,3-dioxygenase (IDO) and that are isolated from the lymph nodes that drain the site of the tumor.

Now, researchers from the Medical College of Georgia, Augusta, have identified how these mouse IDO-expressing pDCs induce tumor-specific immune tolerance.

In the study, which appears online on August 16 in advance of publication in the September print issue of the Journal of Clinical Investigation, David Munn and colleagues found that mouse IDO-expressing pDCs from tumor-draining lymph nodes directly activate the suppressive function of a population of regulatory immune cells characterized as CD4+CD25+Foxp3+ and known as Tregs.

Suppression by Tregs activated by IDO-expressing pDCs was mediated by interactions between programmed cell death 1 (PD1) and its ligands. This mechanism of suppression is distinct from that used by Tregs activated by other stimuli. Importantly, immune suppression in tumor-draining lymph nodes was abrogated by treating mice with both a chemotherapeutic drug and a chemical inhibitor of IDO, but not either agent alone, leading the authors to suggest that combining IDO inhibitors with chemotherapeutic agents might improve the efficacy of chemotherapeutics in individuals with cancer.

Article: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3,-dioxygenase

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

| More

Story Source:

The above story is reprinted from materials provided by Journal of Clinical Investigation, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


APA

MLA

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Search ScienceDaily

Number of stories in archives: 114,963

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

 
  more breaking science news

Social Networks


Recommend this story on Facebook, Twitter,
and Google +1:
Other bookmarking and sharing tools:
| More

Breaking News

... from NewsDaily.com

In Other News ...

Copyright Reuters 2008. See Restrictions.

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

 
Post this page to your favorite social bookmarking site:
close
Include this item in your blog or web site:
close
Cite this article in your essay, paper, or report:
close
Email this page's link to a friend or colleague:
close